OncoMatch/Clinical Trials/NCT07189065
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Is NCT07189065 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Rocbrutinib and Bendamustine for diffuse large b-cell lymphoma (dlbcl).
Treatment: Rocbrutinib · Bendamustine · Rituximab · Lenalidomide — This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with non-GCB DLBCL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody-containing regimen
at least one line must include an anti-CD20 antibody-containing regimen
Cannot have received: BTK inhibitor
Previous refractoriness to BTK-targeting drugs
Cannot have received: autologous stem cell transplant
Exception: within 90 days prior to randomization
Patients who have received autologous stem cell transplantation within 90 days prior to randomization
Cannot have received: allogeneic stem cell transplant
patients who have received allogeneic stem cell transplantation
Cannot have received: (Lobertinib)
Previous exposure to Lobertinib
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify